NO20082069L - 2-Amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-oner - Google Patents
2-Amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-onerInfo
- Publication number
- NO20082069L NO20082069L NO20082069A NO20082069A NO20082069L NO 20082069 L NO20082069 L NO 20082069L NO 20082069 A NO20082069 A NO 20082069A NO 20082069 A NO20082069 A NO 20082069A NO 20082069 L NO20082069 L NO 20082069L
- Authority
- NO
- Norway
- Prior art keywords
- pyrido
- dihydro
- amino
- pyrimidin
- compounds
- Prior art date
Links
- CZOQBGHFZWUWPV-UHFFFAOYSA-N 2-amino-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-one Chemical class O=C1NCCC2=NC(N)=NC=C21 CZOQBGHFZWUWPV-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 208000023345 Autoimmune Diseases of the Nervous System Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 208000035362 autoimmune disorder of the nervous system Diseases 0.000 abstract 1
- 208000015606 cardiovascular system disease Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
Abstract
Det beskrives 2-arnino-7,8-dihydro-6H-pyrido[4,3-d]pyrirnidin-5-on forbindelser, deres stereoisomerer, tautomerer, farmasøytisk akseptable salter og prodrugs derav; preparater som inkluderer en farmasøytisk akseptabel bærer og en eller flere av 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-on forbindelsene, enten alene eller i kombinasjon med minst et ytterligere terapeutisk middel. Det beskrives videre metoder for anvendelse av 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-on forbindelser, enten alene eller i kombinasjon med minst et ytterligere terapeutisk middel, for profylakse eller behandling av cellulære proliferative, virale, autoimmune, kardiovaskulære og sentralnervesystem sykdommer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72279605P | 2005-09-30 | 2005-09-30 | |
| US83688606P | 2006-08-09 | 2006-08-09 | |
| PCT/US2006/038181 WO2007041362A1 (en) | 2005-09-30 | 2006-09-28 | 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20082069L true NO20082069L (no) | 2008-06-09 |
| NO342258B1 NO342258B1 (no) | 2018-04-30 |
Family
ID=37661234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20082069A NO342258B1 (no) | 2005-09-30 | 2008-04-30 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-oner, fremgangsmåte for fremstilling derav og farmasøytiske preparater inneholdende slike |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US7671059B2 (no) |
| EP (1) | EP1928875B1 (no) |
| JP (2) | JP5036002B2 (no) |
| KR (1) | KR101311757B1 (no) |
| AR (1) | AR058072A1 (no) |
| AT (1) | ATE514694T1 (no) |
| AU (1) | AU2006297124B2 (no) |
| BR (1) | BRPI0616701A2 (no) |
| CA (1) | CA2624253C (no) |
| CR (1) | CR9846A (no) |
| CY (1) | CY1112028T1 (no) |
| DK (1) | DK1928875T3 (no) |
| EA (1) | EA016152B1 (no) |
| EC (1) | ECSP088324A (no) |
| GE (1) | GEP20115231B (no) |
| HR (1) | HRP20110655T1 (no) |
| IL (1) | IL190446A0 (no) |
| JO (1) | JO2783B1 (no) |
| MA (1) | MA29885B1 (no) |
| ME (1) | ME01952B (no) |
| MY (1) | MY143604A (no) |
| NO (1) | NO342258B1 (no) |
| NZ (1) | NZ566914A (no) |
| PE (1) | PE20070621A1 (no) |
| PL (1) | PL1928875T3 (no) |
| PT (1) | PT1928875E (no) |
| RS (1) | RS51795B (no) |
| SM (1) | SMP200800029B (no) |
| TN (1) | TNSN08143A1 (no) |
| TW (1) | TWI373471B (no) |
| WO (1) | WO2007041362A1 (no) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| CN101225083A (zh) * | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | 四氢喹唑啉酮类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| GB2449293A (en) * | 2007-05-17 | 2008-11-19 | Evotec | Compounds having Hsp90 inhibitory activity |
| US8071766B2 (en) | 2008-02-01 | 2011-12-06 | Takeda Pharmaceutical Company Limited | HSP90 inhibitors |
| US8759010B2 (en) | 2008-09-26 | 2014-06-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Host cell kinases as targets for antiviral therapies against HCV infection |
| ES2621141T3 (es) * | 2008-11-28 | 2017-07-03 | Novartis Ag | Combinación farmacéutica que comprende un inhibidor de Hsp 90 y un inhibidor de mTOR |
| MX2011005664A (es) * | 2008-11-28 | 2011-06-16 | Novartis Ag | Inhibidores de hsp90 para tratamiento terapeutico. |
| ES2573295T3 (es) * | 2008-11-28 | 2016-06-07 | Novartis Ag | Combinaciones farmacéuticas que comprenden un inhibidor de Hsp90 derivado de isoxazol y el inhibidor de HER2 trastuzumab |
| AR075180A1 (es) * | 2009-01-29 | 2011-03-16 | Novartis Ag | Formulaciones orales solidas de una pirido-pirimidinona |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| MX2012004846A (es) * | 2009-10-29 | 2012-10-05 | Genosco | Inhibidores de cinasa. |
| WO2012104823A2 (en) | 2011-02-04 | 2012-08-09 | Novartis Ag | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases |
| CA2851383A1 (en) | 2011-10-14 | 2013-04-18 | Xizhong Huang | 2 - carboxamide cycloamino urea derivatives in combination with hsp90 inhibitors for the treatment of proliferative diseases |
| ITTO20111013A1 (it) | 2011-11-03 | 2013-05-04 | Dac Srl | Composti farmaceutici |
| CN103664938A (zh) * | 2012-09-12 | 2014-03-26 | 山东亨利医药科技有限责任公司 | 含有嘧啶并环的syk抑制剂 |
| KR20150081344A (ko) | 2012-11-07 | 2015-07-13 | 노파르티스 아게 | 조합 요법 |
| US9677907B2 (en) * | 2013-03-14 | 2017-06-13 | Itron Inc | Intelligent receptacle |
| GB201306610D0 (en) * | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| DK3053578T3 (da) | 2013-09-30 | 2021-02-01 | Taiho Pharmaceutical Co Ltd | Kombinationscancerterapi ved hjælp af azabicycloforbindelse |
| CN106795154B (zh) * | 2014-09-02 | 2019-07-05 | 皮埃尔法布雷医药公司 | 用于治疗癌症的异喹啉酮衍生物 |
| KR20160035411A (ko) * | 2014-09-23 | 2016-03-31 | 주식회사 오스코텍 | LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물 |
| KR101653560B1 (ko) * | 2016-02-02 | 2016-09-12 | 한국화학연구원 | 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물 |
| RU2629599C1 (ru) * | 2016-09-28 | 2017-08-30 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ химиолучевого лечения опухолей прямой кишки и анального канала |
| KR20250007021A (ko) | 2017-06-09 | 2025-01-13 | 추가이 세이야쿠 가부시키가이샤 | N-치환 아미노산을 포함하는 펩타이드의 합성 방법 |
| WO2021261562A1 (ja) * | 2020-06-26 | 2021-12-30 | 日本農薬株式会社 | アリールテトラヒドロピリジン誘導体又はその塩類及び該化合物を含有する殺虫剤並びにその使用方法 |
| JP7756374B2 (ja) * | 2021-03-08 | 2025-10-20 | 曁南大学 | ピリドピリミジン系化合物及びその使用 |
| WO2026027375A1 (de) | 2024-07-29 | 2026-02-05 | Bayer Aktiengesellschaft | Hydroxy-dihydropyridinon carboxamide als schädlingsbekämpfungsmittel |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6165873A (ja) | 1984-09-07 | 1986-04-04 | Mitsui Petrochem Ind Ltd | 2−ピペラジノピリミジン誘導体 |
| CA1307786C (en) | 1984-12-14 | 1992-09-22 | Keiichi Yokoyama | Quinazoline derivatives and antihypertensive preparations containing same as effective components |
| MA21177A1 (fr) * | 1987-02-11 | 1988-10-01 | May & Baker Ltd | Diones cycliques. |
| HU229604B1 (en) * | 2001-02-12 | 2014-02-28 | Hoffmann La Roche | 6-substituted pyrido-pyrimidines, process for their preparation and pharmaceutical compositions containing them |
| DE102004018198A1 (de) | 2004-04-15 | 2005-11-03 | Merck Patent Gmbh | Sulfonamide |
| CA2584485C (en) | 2004-10-20 | 2013-12-31 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| WO2006074293A2 (en) * | 2005-01-07 | 2006-07-13 | President And Fellows Of Harvard College | Bicyclic dihydropyrimidines as eg5 inhibitors |
| MX2007012836A (es) * | 2005-04-14 | 2008-01-11 | Novartis Vaccines & Diagnostic | 2-amino-quinazolin-5-onas como inhibidores de la familia hsp90 que son utiles en el tratamiento de enfermedades de proliferacion. |
-
2006
- 2006-09-26 JO JO2006335A patent/JO2783B1/en active
- 2006-09-28 MY MYPI20080862A patent/MY143604A/en unknown
- 2006-09-28 PL PL06825272T patent/PL1928875T3/pl unknown
- 2006-09-28 NZ NZ566914A patent/NZ566914A/en not_active IP Right Cessation
- 2006-09-28 WO PCT/US2006/038181 patent/WO2007041362A1/en not_active Ceased
- 2006-09-28 SM SM200800029T patent/SMP200800029B/it unknown
- 2006-09-28 KR KR1020087010134A patent/KR101311757B1/ko not_active Expired - Fee Related
- 2006-09-28 ME MEP-2011-334A patent/ME01952B/me unknown
- 2006-09-28 GE GEAP200610671A patent/GEP20115231B/en unknown
- 2006-09-28 AU AU2006297124A patent/AU2006297124B2/en not_active Ceased
- 2006-09-28 RS RS20110334A patent/RS51795B/sr unknown
- 2006-09-28 PE PE2006001177A patent/PE20070621A1/es not_active Application Discontinuation
- 2006-09-28 AT AT06825272T patent/ATE514694T1/de active
- 2006-09-28 PT PT06825272T patent/PT1928875E/pt unknown
- 2006-09-28 BR BRPI0616701-2A patent/BRPI0616701A2/pt not_active IP Right Cessation
- 2006-09-28 US US11/541,462 patent/US7671059B2/en active Active
- 2006-09-28 AR ARP060104292A patent/AR058072A1/es unknown
- 2006-09-28 DK DK06825272.5T patent/DK1928875T3/da active
- 2006-09-28 JP JP2008533697A patent/JP5036002B2/ja not_active Expired - Fee Related
- 2006-09-28 EP EP06825272A patent/EP1928875B1/en active Active
- 2006-09-28 EA EA200800992A patent/EA016152B1/ru not_active IP Right Cessation
- 2006-09-28 HR HR20110655T patent/HRP20110655T1/hr unknown
- 2006-09-28 CA CA2624253A patent/CA2624253C/en not_active Expired - Fee Related
- 2006-09-29 TW TW095136162A patent/TWI373471B/zh not_active IP Right Cessation
-
2008
- 2008-03-26 IL IL190446A patent/IL190446A0/en not_active IP Right Cessation
- 2008-03-28 TN TNP2008000143A patent/TNSN08143A1/en unknown
- 2008-03-28 EC EC2008008324A patent/ECSP088324A/es unknown
- 2008-03-28 CR CR9846A patent/CR9846A/es unknown
- 2008-04-24 MA MA30873A patent/MA29885B1/fr unknown
- 2008-04-30 NO NO20082069A patent/NO342258B1/no not_active IP Right Cessation
-
2009
- 2009-07-31 US US12/462,302 patent/US20100004237A1/en not_active Abandoned
-
2011
- 2011-08-09 CY CY20111100758T patent/CY1112028T1/el unknown
-
2012
- 2012-05-25 JP JP2012119613A patent/JP2012158611A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN08143A1 (en) | 2-amino-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-ones | |
| NO20052805L (no) | Substituerte pyrrolo-pyrazolderivater som kinase-inhibitorer | |
| NO20072984L (no) | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment | |
| DK1377589T3 (da) | Oxazolyl-pyrazolderivater som kinaseinhibitorer | |
| WO2007022073A3 (en) | Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives | |
| MX2009012595A (es) | Derivados de espiroindolinona. | |
| TW200718689A (en) | 2-Amino-quinazolin-5-ones | |
| IL191160A (en) | Use of pyrido [3,2- b] pyrazine-6-yl urine urine for the preparation of drugs to treat diseases caused by the enzyme pi3k inhibition. | |
| CY1112478T1 (el) | Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες | |
| NO20076055L (no) | Imidazo- og triazolopyridiner som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase type I | |
| WO2008067389A3 (en) | Modulation of sod protein synthesis for the treatment of neurodegenerative diseases | |
| BR112014015720A2 (pt) | derivados de tieno[3,2-d]pirimidina que têm atividade inibidora de proteinas quinases | |
| WO2010099379A8 (en) | Jak kinase modulating quinazoline derivatives and methods of use thereof | |
| NO20076054L (no) | Imidiazo - og triazolopyridiner som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase type I | |
| WO2008149382A8 (en) | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application | |
| NO20082065L (no) | Nye imidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase 3 for anvendelse ved behandling av demens og neurodegenerative forstyrrelser | |
| NO20092251L (no) | Pyrrolo [2,3-B] pyridinderivater som kinasemodulatorer | |
| WO2005070930A3 (en) | Tetrahydrocarboline compounds as anticancer agents | |
| WO2008079159A3 (en) | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | |
| MX2010002733A (es) | Terapia de intervalo para el tratamiento de tinnitus. | |
| WO2005084192A3 (en) | Novel 2’-c-methyl nucleoside derivatives | |
| MX356644B (es) | Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson. | |
| GEP20105095B (en) | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | |
| WO2008045378A3 (en) | Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin | |
| WO2002070515A3 (en) | Chromane derivatives, process for their preparation and their use as antitumor agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |